Agenus said it will present long-term survivor data on BOT+BAL in refractory MSS metastatic colorectal cancer at SITC 2026. The update also includes translational research on BOT+BAL with agenT-797, extending visibility into its CRC pipeline.
published
Agenus said it will present long-term survivor data on BOT+BAL in refractory MSS metastatic colorectal cancer at SITC 2026. The update also includes translational research on BOT+BAL with agenT-797, extending visibility into its CRC pipeline.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.